Literature DB >> 11778975

Vinorelbine-associated myelopathy in a patient who previously received paclitaxel: a case report.

J Y Han1, B G Choi, D H Song, J G Ahn, J S Yoon, K S Lee.   

Abstract

Vinorelbine seems to cause less neurotoxicity than other vinca alkaloids because of its selective activity on mitotic cells over axonal microtubules. Clinical trials report very mild peripheral neurotoxicity with distal paresthesiae and there are no reports of myelopathy in these series of patients. The authors describe a patient who developed a rare event of myelopathy while on vinorelbine for non-small-cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11778975     DOI: 10.1385/MO:18:1:95

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  6 in total

1.  Severe neurotoxicity from vinorelbine-paclitaxel combinations.

Authors:  D Parimoo; S Jeffers; F M Muggia
Journal:  J Natl Cancer Inst       Date:  1996-08-07       Impact factor: 13.506

2.  Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients.

Authors:  A Pace; L Bove; C Nisticò; M Ranuzzi; P Innocenti; A Pietrangeli; E Terzoli; B Jandolo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

3.  Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel--a phase II study.

Authors:  B Fazeny; U Zifko; S Meryn; H Huber; W Grisold; C Dittrich
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  A summary of vinorelbine (Navelbine) safety data from North American clinical trials.

Authors:  J A Hohneker
Journal:  Semin Oncol       Date:  1994-10       Impact factor: 4.929

Review 5.  Neurologic complications of chemotherapy.

Authors:  D R Macdonald
Journal:  Neurol Clin       Date:  1991-11       Impact factor: 3.806

6.  Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.

Authors:  G Gasparini; O Caffo; S Barni; L Frontini; A Testolin; R B Guglielmi; G Ambrosini
Journal:  J Clin Oncol       Date:  1994-10       Impact factor: 44.544

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.